Study part A ( 66 healthy subjects ) was a single-dose , open-label , randomized , 2-period crossover study to evaluate the BE of the dolutegravir/abacavir/lamivudine FDC tablet and dolutegravir + abacavir/lamivudine tablets in the fasted state .